Paclitaxel and topotecan in combination with rituximab as effective salvage regimen in relapsed or refractory aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Canales, MA
Sanjurjo, MJ
Garcia-Vela, JA
de Paz, R
Gracia, J
Hernandez, D
Bustos, JG
Hernandez-Navarro, F
机构：
[1] Hosp Univ La Paz, Dept Hematol, Madrid, Spain
[2] Hosp Univ Getafe, Dept Hematol, Getafe, Spain
[3] Univ Autonoma Madrid, E-28049 Madrid, Spain
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4877
引用
收藏
页码：289B / 289B
页数：1
相关论文
共 50 条
  • [1] Paclitaxel and topotecan in combination with rituximab as effective second-line salvage regimen in resistant aggressive non-Hodgkin's lymphoma
    Canales, M
    Sanjurjo, M
    García-Vela, J
    de Paz, R
    Cobo, T
    de la Guía, AL
    Martín, M
    Hernández, D
    Bustos, JG
    Hernández-Navarro, F
    ANNALS OF ONCOLOGY, 2005, 16 : 181 - 181
  • [2] Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Westin, Jason R.
    McLaughlin, Peter
    Romaguera, Jorge
    Hagemeister, Fredrick B.
    Pro, Barbara
    Dang, Nam H.
    Samaniego, Felipe
    Rodriguez, Maria A.
    Fayad, Luis
    Oki, Yasuhiro
    Fanale, Michelle
    Fowler, Nathan
    Nastoupil, Loretta
    Feng, Lei
    Loyer, Evelyn
    Younes, Anas
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (02) : 177 - 184
  • [3] Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
    Younes, A
    Preti, HA
    Hagemeister, FB
    McLaughlin, P
    Romaguera, JE
    Rodriguez, MA
    Samuels, BI
    Palmer, JL
    Cabanillas, F
    ANNALS OF ONCOLOGY, 2001, 12 (07) : 923 - 927
  • [4] Paclitaxel plus topotecan plus rituximab (TTR): An effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL)
    Younes, A
    McLaughlin, P
    Romaguera, J
    Hagemeister, F
    Pro, B
    Dang, N
    Samaniego, F
    Rodriguez, M
    Fayad, L
    ANNALS OF ONCOLOGY, 2005, 16 : 101 - 102
  • [5] Response to re-treatment with rituximab plus salvage-chemotherapy in refractory or relapsed aggressive Non-Hodgkin's lymphoma.
    Borgerding, Andrea
    Hasenkamp, Justin
    Chapuy, Bjoern
    Truemper, Lorenz
    Wulf, Gerald
    Glass, Bertram
    BLOOD, 2006, 108 (11) : 262B - 263B
  • [6] A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/refractory aggressive histology non-Hodgkin's lymphoma.
    Piliotis, EG
    Mangel, J
    Buckstein, R
    Imrie, K
    Spaner, D
    Reis, M
    Foden, C
    Boudreau, A
    Richardson, P
    Richardson, J
    Berinstein, N
    BLOOD, 2003, 102 (11) : 288B - 288B
  • [7] Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Weidmann, E
    Kim, SZ
    Rost, A
    Schuppert, H
    Seipelt, G
    Hoelzer, D
    Mitrou, PS
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1285 - 1289
  • [8] FLUDAP: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma
    Child, JA
    Johnson, SA
    Rule, S
    Smith, GM
    Morgan, GJ
    Johnson, PWM
    Prentice, AG
    Tollerfield, SM
    Wareham, E
    LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 309 - 317
  • [9] Phase II study of paclitaxel plus topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes, A
    Rahman, D
    Hagemeister, F
    Romaguera, J
    McLaughlin, P
    Cabanillas, F
    BLOOD, 1998, 92 (10) : 621A - 621A
  • [10] Phase II study of Paclitaxel plus Topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes, A
    Okpara, N
    Romaguera, JE
    Hagemeister, FB
    McLaughlin, P
    Rahman, D
    Cabanillas, F
    BLOOD, 1999, 94 (10) : 270B - 270B
12345